MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in vinorelbine-resistant breast cancer cells

Gene

Volumn 556, Issue 2, 2015, Pages 113-118

  Zhong, Shanliang ^a   Ma, Tengfei ^a   Zhang, Xiaohui ^a   Lv, Mengmeng ^b   Chen, Lin ^c   Tang, Jinhai ^a   Zhao, Jianhua ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Chemotherapy; MiRNAs; Resistance

Indexed keywords

CYCLIN D1; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN; ANTINEOPLASTIC AGENT; VINBLASTINE;

ARTICLE; BIOINFORMATICS; BREAST CANCER CELL LINE; CANCER RESISTANCE; CCND1 GENE; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; GENE; GENE EXPRESSION PROFILING; GENE MAPPING; GENE ONTOLOGY; GRB2 GENE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NT5E GENE; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICRORNAS; VINBLASTINE;

EID: 84919681039     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.11.046     Document Type: Article

References (27)

1. Anglicheau D., Muthukumar T., Suthanthiran M. MicroRNAs: small RNAs with big effects. Transplantation 2010, 90:105-112.
2. Chang H., Jeung H.C., Jung J.J., Kim T.S., Rha S.Y., Chung H.C. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res. Treat. 2011, 125:55-63.
3. Chen G.Q., Zhao Z.W., Zhou H.Y., Liu Y.J., Yang H.J. Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med. Oncol. 2010, 27:406-415.
4. Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005, 33:1290-1297.
5. Degardin M., Bonneterre J., Hecquet B., Pion J.M., Adenis A., Horner D., Demaille A. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann. Oncol. 1994, 5:423-426.
6. Di Fulvio M., Henkels K.M., Gomez-Cambronero J. Short-hairpin RNA-mediated stable silencing of Grb2 impairs cell growth and DNA synthesis. Biochem. Biophys. Res. Commun. 2007, 357:737-742.
7. Enright A.J., Van Dongen S., Ouzounis C.A. An efficient algorithm for large-scale detection of protein families. Nucleic Acids Res. 2002, 30:1575-1584.
8. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
9. Hui C., Xiaoli P., Qian B., Yong Z., Xiaoping Y., Qianyong Z., Jundong Z., Mantian M. Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signalling pathway. Carcinogenesis 2014, 35:1847-1854.
10. Kutanzi K.R., Yurchenko O.V., Beland F.A., Checkhun V.F., Pogribny I.P. MicroRNA-mediated drug resistance in breast cancer. Clin. Epigenetics 2011, 2:171-185.
11. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294:853-858.
12. Li J.H., Liu S., Zhou H., Qu L.H., Yang J.H. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014, 42:D92-D97.
13. Loh Y.N., Hedditch E.L., Baker L.A., Jary E., Ward R.L., Ford C.E. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer 2013, 13:174.
14. Morris J.H., Apeltsin L., Newman A.M., Baumbach J., Wittkop T., Su G., Bader G.D., Ferrin T.E. clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC Bioinforma. 2011, 12:436.
15. O'Driscoll L., Clynes M. Biomarkers and multiple drug resistance in breast cancer. Curr. Cancer Drug Targets 2006, 6:365-384.
16. Rivera E., Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res. 2010, 12(Suppl. 2):S2.
17. Saito R., Smoot M.E., Ono K., Ruscheinski J., Wang P.L., Lotia S., Pico A.R., Bader G.D., Ideker T. A travel guide to Cytoscape plugins. Nat. Methods 2012, 9:1069-1076.
18. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
19. Smith G.A. Current status of vinorelbine for breast cancer. Oncology (Williston Park) 1995, 9:767-773. (discussion 774, 776, 779).
20. Sun G., Shi L., Yan S., Wan Z., Jiang N., Fu L., Li M., Guo J. MiR-15b targets cyclin D1 to regulate proliferation and apoptosis in glioma cells. Biomed Res. Int. 2014, 2014:687826.
21. Szklarczyk D., Franceschini A., Kuhn M., Simonovic M., Roth A., Minguez P., Doerks T., Stark M., Muller J., Bork P., Jensen L.J., von Mering C. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011, 39:D561-D568.
22. Ujhazy P., Berleth E.S., Pietkiewicz J.M., Kitano H., Skaar J.R., Ehrke M.J., Mihich E. Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int. J. Cancer 1996, 68:493-500.
23. Wind N.S., Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int. J. Breast Cancer 2011, 2011:967419.
24. Yang X.L., Lin F.J., Guo Y.J., Shao Z.M., Ou Z.L. Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways. Onco Targets Ther. 2014, 7:1033-1042.
25. Yin J., Cai Z., Zhang L., Zhang J., He X., Du X., Wang Q., Lu J. A recombined fusion protein PTD-Grb2-SH2 inhibits the proliferation of breast cancer cells in vitro. Int. J. Oncol. 2013, 42:1061-1069.
26. Yoo Y.A., Kim Y.H., Kim J.S., Seo J.H. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer. Biochim. Biophys. Acta 2008, 1783:438-447.
27. Zhong S., Li W., Chen Z., Xu J., Zhao J. miR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 2013, 531:8-14.